PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-1.55%
Negative revenue growth while AVGO stands at 6.32%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
3.51%
Gross profit growth at 50-75% of AVGO's 4.96%. Martin Whitman would question if cost structure or brand is lagging.
5.06%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
5.06%
Operating income growth above 1.5x AVGO's 1.00%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
16.13%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
15.63%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
10.00%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.18%
Share count expansion well above AVGO's 0.15%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.19%
Diluted share reduction more than 1.5x AVGO's 0.70%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-47.14%
Negative OCF growth while AVGO is at 9.32%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-76.13%
Negative FCF growth while AVGO is at 9.56%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
386.85%
Similar 10Y revenue/share CAGR to AVGO's 416.86%. Walter Schloss might see both firms benefiting from the same long-term demand.
416.09%
5Y revenue/share CAGR above 1.5x AVGO's 134.28%. David Dodd would look for consistent product or market expansions fueling outperformance.
21.27%
3Y revenue/share CAGR under 50% of AVGO's 62.33%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
1047.86%
10Y OCF/share CAGR above 1.5x AVGO's 580.47%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
200.98%
5Y OCF/share CAGR above 1.5x AVGO's 92.77%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
6289.46%
3Y OCF/share CAGR above 1.5x AVGO's 39.51%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
637.92%
Net income/share CAGR at 50-75% of AVGO's 869.72%. Martin Whitman might question if the firm’s product or cost base lags behind.
408.37%
5Y net income/share CAGR similar to AVGO's 414.43%. Walter Schloss might see both on parallel mid-term trajectories.
1184.03%
3Y net income/share CAGR above 1.5x AVGO's 16.00%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
921.18%
10Y equity/share CAGR in line with AVGO's 862.23%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
846.67%
5Y equity/share CAGR above 1.5x AVGO's 165.61%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
30.11%
Below 50% of AVGO's 201.93%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
39.23%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-2.21%
Inventory is declining while AVGO stands at 8.08%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
5.70%
Asset growth above 1.5x AVGO's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
3.45%
50-75% of AVGO's 5.15%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-100.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-0.12%
Our R&D shrinks while AVGO invests at 13.26%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
7.54%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.